Vera Therapeutics Inc [VERA] stock is trading at $41.62, up 9.79%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The VERA shares have gain 5.10% over the last week, with a monthly amount drifted -3.61%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 2, April 2024, Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress. In a post published today on Yahoo Finance, 72-week data of atacicept in IgAN accepted as a best-ranked abstract.
From an analyst’s perspective:
Vera Therapeutics Inc [NASDAQ: VERA] stock has seen the most recent analyst activity on January 25, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $26. On December 18, 2023, Raymond James initiated with a Outperform rating and assigned a price target of $29 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $26 on November 10, 2023. Guggenheim initiated its recommendation with a Buy and recommended $27 as its price target on August 16, 2023. Wedbush downgraded its rating to Neutral for this stock on January 04, 2023, and downed its price target to $8. In a note dated January 04, 2023, Jefferies downgraded an Hold rating on this stock and revised its target price from $32 to $6.
Vera Therapeutics Inc [VERA] stock has fluctuated between $5.95 and $50.78 over the past year. Currently, Wall Street analysts expect the stock to reach $26 within the next 12 months. Vera Therapeutics Inc [NASDAQ: VERA] shares were valued at $41.62 at the most recent close of the market. An investor can expect a potential drop of -37.53% based on the average VERA price forecast.
Analyzing the VERA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -0.73 and Total Capital is -0.67. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.51.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 37.47 points at the first support level, and at 33.32 for the second support level. However, for the 1st resistance point, the stock is sitting at 44.16, and for the 2nd resistance point, it is at 46.70.
Vera Therapeutics Inc [VERA] reported earnings per share of -$0.6 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.51/share, meaning a difference of -$0.09 and a surprise factor of -17.60%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.45 per share as compared to estimates of -$0.53 per share, a difference of $0.08 representing a surprise of 15.10%.
Ratios To Look Out For
For context, Vera Therapeutics Inc’s Current Ratio is 7.42. In addition, the Quick Ratio stands at 7.42 and the Cash Ratio stands at 2.05.
Transactions by insiders
Recent insider trading involved Grant Sean, CHIEF FINANCIAL OFFICER, that happened on Apr 03 ’24 when 99828.0 shares were sold. CHIEF FINANCIAL OFFICER, Grant Sean completed a deal on Apr 03 ’24 to sell 18649.0 shares. Meanwhile, Director Katabi Maha sold 0.34 million shares on Mar 25 ’24.
